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Until recently gluten intolerance has been believed to be typical of celiac disease (CD) and wheat allergy
(WA). In the last few years, however, several study results have been published that have proved that
gluten intolerance can also affect people who do not suffer from any of the above mentioned diseases.
The new syndrome has been named non-celiac gluten sensitivity (NCGS) or gluten sensitivity (GS). It has
been included in the new list of gluten-related disorders published in 2012. Researchers believe that
NCGS is the most common syndrome of gluten intolerance. This review discusses many aspects of NCGS
epidemiology, pathophysiology, clinical spectrum, and treatment and current tools to identify patients
suffering from CD, WA, and NCGS.
© 2014 The Author. Published by Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).Non-celiac gluten sensitivity (NCGS) is a new syndrome of
gluten intolerance. In literature some other names have been sug-
gested for this disorder, such as gluten sensitivity (GS), gluten hy-
persensitivity or non-celiac gluten intolerance [1e5]. Its ﬁrst name
was GS and it was proposed in 2011 by members of the First Expert
Meeting on GS [1]. Later, a group of 16 experts who announced a
new deﬁnition (the Oslo Deﬁnition) of celiac disease suggested that
instead of GS the disorder should be named NCGS, which made it
distinguishable from CD [4]. The Second Expert Meeting on GS that
was held in Munich in 2012, decided to change the name of this
disorder to NCGS in order to avoid confusion with CD [6].
The ﬁrst reports about this diseases date back to 30 years ago,
but not until recently have numerous reports appeared, primarily
about adults, which demonstrate that there is a group of patients
whose symptoms have disappeared with gluten withdrawal from
diet and they are not affected with either celiac disease (CD) or
wheat allergy (WA) [7]. The ﬁrst case reports of NCGS in children
were described in 2012 [8].
NCGS can be diagnosed in those patients with gluten intolerance
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d/3.0/).WA and who do not suffer from lesions in the duodenal mucosa,
which is characteristic of CD. The gluten-free diet leads to complete
regression of symptoms [1,3,9]. The overall prevalence of NCGS in
the general population is still unknown, mainly because many
patients are currently self-diagnosed and start a gluten-free diet
(GFD) without medical advice or consultation [6]. The disorder
seems to be more common in females and in young/middle age
adults [6]. Some authors think that the incidence of NCGS seems to
be higher than CD and WA, its estimated numbers reaching 0,
63e6% of the population [5,10e12].
1. Genetic background
Half of the NCGS patients have the genes encoding DQ2 or DQ8
molecules in their HLA system [1,6]. It has also been reported that
HLA-DQ2 genes are frequently observed in patients with NCGS and
with the diarrhoea-predominant irritable bowel syndrome (IBS)
[13]. The genes encoding DQ2 or DQ8 molecules (their markers are
commonly used in the disease diagnostics) are present in 95% of the
CD patients. Negative results for both HLA-DQ2 and HLA-DQ8
excluded the diagnosis of CD in at least 95% (>95% negative pre-
dictive value). These genes are present in healthy people as well
(30%), but less frequently than in the case of the NCGS patients
(50%) [1].
2. Clinical manifestation
NCGS is characterized by symptoms that usually occur after
gluten ingestion, disappear with gluten withdrawal from diet andal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
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from NCGS are a heterogenous group, composed of several sub-
groups, each characterized by different pathogenesis and clinical
course.
The typical presentation of NCGS is a combination of IBS-like
symptoms, and systemic manifestations such as headache, joint
and muscle pain, muscle contractions, leg or arm numbness,
chronic fatigue, “foggy mind”, body mass loss and anaemia or they
can include behaviour disturbances such as the disturbance in
attention and depression (Table 1) [3,5,6,10,15]. IBS-like symptoms
including abdominal pain, nausea, bloating, ﬂatulence, diarrhoea or
constipation. In children, NCGSmanifests with intestinal symptoms
(abdominal pain and chronic diarrhoea), the extra-intestinal
manifestations seem to be less frequent - the most common
extra-intestinal symptom being tiredness [8,16].
In people with dyspepsia the increased incidence of NCGS was
not observed [17]. Yet, NCGS is increasingly often diagnosed in
patients with IBS, especially in those with its diarrhoea-
predominant and mixed form [9,18]. Then it is referred to as
gluten-sensitive irritable bowel syndrome [18]. Massari et al.
report that NCGS is also frequently observed in allergic subjects
with allergic disorders [19]. Volta et al. have also proven that
NCGS is frequent (13%) in the CD patients' ﬁrst degree relatives
[20].
3. Histological manifestation
The NCGS patients' gastrointestinal tracts and their intestinal
permeability are normal and the lesions in the histological picture
of their duodenal mucosa are minor [21]. They present the IEL
growth in epithelium (g and d class) [10]. Additionally, lymphocytic
inﬁltrations in mucosa were observed which are rated at 0 or I in
Marsh's classiﬁcation [1,3,10,15,21].
Partial or subtotal villous atrophy with crypt hyperplasia is
typical of CD and is rated as Marsh III and IV [22]. The CD patients
had increased numbers of CD3þ IELs (>25/100 enterocytes), while
NCGS and WA patients had a number of CD3þ IELs intermediate
between CD patients and controls.Table 1
Symptoms of non-celiac gluten sensitivity disorders (NCGS).
Disturbances
Intestinal
 Abdominal pains (68%)a
 Diarrhoea (33%)a
 Nausea






 Headache (35%), bone and joint pain (11%)a
 Muscle contractions (34%)a
 Numbness of hands and feet (20%)a









 Chronic ulcerative stomatitis
a 347 patients treated at the Center for Celiac Research University of Maryland in
2004e2010 [1].Minor abnormalities (mildly inﬂamed mucosa) in the histolog-
ical picture, i.e. Marsh I, are observed much more frequently than
CD itself. They have been recently referred to as lymphocytic en-
teropathy. They occur in NCGS and in other diseases, e.g. in food
allergy [23]. Marsh I and II lesions can also be the initial phase of
mucosal atrophy in CD, but then patients develop more antibodies
characteristic of the CD, mainly anti-transglutaminase (tTG) and
anti-endomysium (EMA) antibodies, which does not take place in
the case of NCGS [24]. Recently, increased inﬁltration of duodenal
lamina propria with eosinophils and activation of circulating ba-
sophils have been described in NCGS patients [25,26].
4. Diagnosis
The major dilemma in clinical practice is how to recognise the
syndrome that is gluten-dependent but does not meet the criteria
of CD and WA [5]. The diagnosis cannot be made until CD and WA
have been eliminated (Table 2). The diagnosis is conﬁrmed by a
food provocation test, i.e. the same test which is applied in the WA
diagnostics. The food challenge procedure is performed by means
of an open test (if the symptoms are objective e vomiting, diar-
rhoea) or a blind test (when the symptoms are subjective e
abdominal pain, nausea, headache, tiredness). In NCGS the adverse
symptoms appear several hours or days after gluten consumption,
while in IgE-dependent WA symptoms appear within 2 h from the
food intake [3,6]. In scientiﬁc studies, as well as in the diagnostics of
other advere reactions to food, food challenge must be performed
my means of a double-blind placebo controlled test. However, the
standards of food challenge tests in NCGS patients have not been
yet developed, therefore the researchers use the protocols adopted
in the diagnostics of adverse reactions to food. Experts recommend
food challenge with wheat to be performed after at least 3 weeks of
the gluten-free diet [6].
There are no laboratory markers speciﬁc to NCGS. It is still a
major limitation of clinical studies, making the differential diag-
nosis with other gluten-related disorders difﬁcult. The only known
antibodies observed in the NCGS patients are IgG antigliadin anti-
bodies (IgG-AGA) which, unfortunately, occur in only a half of the
patients [20].
5. Antigliadin antibodies, AGA
AGA are produced in response to wheat gliadin. They have been
used in diagnostics since 1980. For some time the IgA AGA ELISAs
were used to diagnose CD but today, due to the fact that their
sensitivity and speciﬁcity are lower (60.9%e96% and 79.4%e93.8%)
than EMA (90% and94.7%) and tTG ELISAs antibodies (90% and
90%), they are not recommended in the CD diagnostics where
they are employed only to diagnose children younger than 18
months whose IgA-AGA sensitivity is high (97.2%) and speciﬁcity is
lower (83.2%) [27e30].
Also, the IgA-AGA antibodies are present in patients with some
autoimmune diseases including the conditions that are both
gluten-sensitive (Dühring's disease, gluten ataxia) and gluten-
insensitive (rheumatoid arthritis, Sjӧgren's syndrome, systemic
lupus erythematosus, sarcoidosis) [18].
Healthy people develop AGA antibodies only in the IgG class
with the frequency of 2e8%. They are observed in ¼ of patients
presenting with increased intestinal permeability, that is in in-
ﬂammatory gastrointestinal disorders, food allergy and atopic
dermatitis [20]. In these groups of patients high levels of AGA an-
tibodies only in the IgG class have been observed.
The IgG-AGA antibodies are also present in some patients with
NCGS, yet their share is smaller than in the case of CD. As Volta at al.
observed, IgG-AGAwere detected in 56.4% of the NCGS patients and
Table 2
Characteristics of gluten-dependent disorders.




Genetic background In 95%: HLA-DQ2 or HLA-DQ8 In 50%: HLA-DQ2 or HLA-DQ8 In 100% atopy
Pathogenic mechanisms Disturbances in the acquired immune
response to gluten depend on the combination
of HLA-DQ2 and HLA-DQ8
Unknown, probably the disturbances
in the primary immune response
to gluten
IgE-dependent reactions, prevalent Th2
combination in the immune response
to wheat allergens
Antibodies in serum tTGa, EMAa, DGPa, AGA primarily in the IgA
class, less frequently in the IgG class
In 50%: IgG-AGAa sIgE for wheat
sIgE for u5-gliadin (in anaphylaxis)
in 25%: IgG-AGA
Histology of duodenal mucosa Marsh I-IV, prevalent Marsh III i IV Marsh 0,I Marsh 0,I,II
Atrophy of duodenal villi Present Absent May be present
Symptoms Intestinal and extraintestinal Intestinal and extraintestinal Intestinal and extraintestinal
Mortality Increased Unknown Increasedb
Time of gluten-free diet durationc Lifelong Unknown The average of 6 years, individual;
lifelong in anaphylaxis
a tTG e Tissue transglutaminase, EMA e Endomysium antibodies, DGP e Deamidated gliadin peptide, AGA e Antigliadin antibodies.
b In anaphylaxis after wheat consumption.
c In wheat allergy only wheat is eliminated from the diet.
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respectively [20]. Thus IgG-AGA cannot be regarded as the NCGS
marker, although they can be useful when there is a need to
conﬁrm the syndrome in the situation when CD and WA have been
ruled out and a patient responds to a gluten-free diet. The IgG-AGA
concentrations in the CD and NCGS patients do not differ signiﬁ-
cantly [20]. The vast majority of NCGS patients showed IgG-AGA
disappearance after gluten withdrawal. The same antibodies per-
sisted in 40% of CD patients after gluten-free diet [31]. In NCGS
patients the negativization of IgG-AGA was signiﬁcantly related to
good clinical response to gluten-free diet [31].6. Irritable bowel syndrome, IBS
At present it is recommended to perform serological screening
for CD in patients with IBS, particularly in those who suffer from its
diarrhoea-predominant and mixed form, as it has been proven that
in their case the incidence of CD is 4 times higher [32e34].
It also is a well-known fact that persistent minor inﬂammation
of duodenal mucosa can lead to IBS. Such lesions are observed in
patients with both WA and NCGS, so their presence can predispose
such patients to IBS. As early as in 1993 Arranz and Ferguson
conﬁrmed that some IBS patients could develop NCGS [35]. They
demonstrate a high level of IgA-AGA and a gluten-sensitive diar-
rhoea, but there is no enteropathy typical of CD. Recently many
authors have pointed out that NCGS is frequent in patients with IBS,
especially presenting with its diarrhoea-predominant and mixed
form [9,11,13,14,18]. The disorder is then called a gluten-sensitive
irritable bowel syndrome. In the large study performed by Car-
roccio et al., 30% subjects with IBS-like symptoms were suffered
fromwheat sensitivity [25]. Vazquez-Roque at al. proved that in IBS
patients gluten altered intestine barrier functions, particularly in
HLA-DQ2/8epositive patients. GFDmay improve patient symptoms
in IBS [36].
The IBS patients who respond well to a GFD can suffer from one
of the three diseases: CD, WA or NCGS, where NCGS is the most
likely option (Fig. 1). The presence of IgA-tTG and eEMA and the
atrophy of duodenal villi (Marsh III and IV) support the CD diag-
nosis in patients without IgA deﬁciency. The presence of sIgE for
wheat, a positive food challenge and minimal histological lesions
(Marsh 0,1) conﬁrmWA, while the absence of markers typical of CD
andWA and minor histological lesions (Marsh 0,1) accompanied by
a good response to a GFD indicate NCGS [9]. The presence of AGA
antibodies is an additional marker for NCGS in those patients.7. Neuropsychiatric syndromes: autism spectrum disorders
(ASD) and schizophrenia
In the past two decades several studies have been published
discussing the incidence of NCGS in subjects with Schizophrenia
and autism spectrum disorders (ASD).
One of the most popular interventions for ASD is the gluten-free
casein free (GFCF) diet. Marcason at al. hypothesized that some
symptoms may be caused in the ASD patients by opioid peptides
formed from the incomplete breakdown of foods containing gluten
and casein [37].
Increased intestinal permeability which occurs in children with
ASD allows these peptides to cross the intestinal membrane, enter
the blood, and cross the blood-brain barrier, affecting the endog-
enous opiate system and neurotransmission within the nervous
system. The resulting excess of opioids is thought to lead to be-
haviours noted in ASD. Removal of these substances from the diet
could determine a change in autistic behaviours. In the fact only a
small group of children affected by ASD may beneﬁt from an GFCF
diet indicating that autism may be part of the spectrum of NCGS, at
least in some cases. Despite its popularity, the efﬁcacy of this diet in
improving autistic behaviour remains not proven [38].
A recent study found that some schizophrenic patients present
high level of AGA IgG and anti-tTG antibodies, but only 2% of
schizophrenic patients fulﬁlled the CD diagnostic criteria (both
anti-tTG and anti-EMA positive) [39,40]. Additional studies
revealed that most of the tTG positive subjects were tTG-6 positive.
Anti-tTG-6 is mostly expressed by a particular subset of neurons in
the CNS. It is thought to be a biomarker of neuro-inﬂammation [41].
Other studies conﬁrmed the high prevalence of antibodies to AGA
among people with schizophrenia [42]. In some patients on the
GFD the improvement of symptoms was observed. The authors
believe that a subgroup of schizophrenics may suffer from food
intolerances or that circulating food-derived peptides (exorphins)
exert an inﬂuence on physiological processes in their brains
through the same mechanism as in the autism patients.
Today the role of NCGS in diseases affecting the nervous system
still remains a controversial and requires additional studies [6].8. Pathogenesis
Aetiologically NCGS is a disorder with poorly recognised path-
ogenesis [5]. It has not been determined yet what grain ingredients
are responsible for the symptoms of the disease. Upon incubation
Fig. 1. Clinical presentation of irritable bowel syndrome (IBS).
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duodenal mucosa in the patients with CD e does not express
markers of inﬂammation and their basophils are not activated by
gliadin [43]. Another studies suggest that wheat amylase trypsin
inhibitors (ATIs) could play a major role as triggers of the innate
immune response leading to NCGS [44]. Eswaran et al. believe that
this role can be played by the poorly absorbed carbohydrates in
wheat grains e fructo-oligosaccharides, fructans (FODMAPs) [45].
In all NCGS patients gastrointestinal IBS-like symptoms signiﬁ-
cantly improved during reduced FODMAP intake. During fermen-
tation gas is produced and short-chain fatty acid are formed. What
is more, changes in microbiota take place resulting in gastrointes-
tinal symptoms. FODMAPs are also present in many other plants.
Today, it is believed that they trigger IBS symptoms [46,47].
Contrary to CD, where the secondary immune response is up-
regulation, the NCGS patients demonstrate mainly up-regulation
of the primary response [10,21]. There is no increased expression
of the genes of the secondary immune response including IL-6, IL-
21 and INFg, which is characteristic of CD [1]. In the intestinal
mucosa there is an increased expression of tolk-like receptors 1, 2
and 4 of the primary immune response. Other relevant differences
between the CD and NCGS patients are observed in the intestinal
barrier function on the level of the epithelial cell tight junction. The
CD subjects manifest increased intestinal permeability and raised
claudin-1 and zonulin expression, while the NCGS patients
demonstrate normal intestinal permeability and a normal level ofthe above proteins, but the expression of CLDN4 gene, which syn-
thesizes claudine-4, is high. In the NCGS patients TGFb1 and the
FoxP3 markers for regulatory lymphocytes 3 are signiﬁcantly
reduced, which indicates the likelihood of the recruitment of the
regulatory T lymphocytes to the small intestine to be smaller than
in healthy people. Brottveit et al. showed that after gluten challenge
NCGS patients only had increased IFN-g levels and increased den-
sity of intraepithelial CD3(þ) T cells at baseline but CD patients had
a concomitant innate and adaptive immune response [48]. This
indicates that the adaptive immune response may play a role in the
NCGS pathogenesis.
So far there are no reports comparing the immunological dis-
orders in the intestinal mucosa in WA and NCGS.
9. Gluten-related disorders
In 2011 in London a panel of 15 experts announced a new clas-
siﬁcation of gluten-related disorders that was then published in
February2012 (Fig. 2) [1]. Catassi et al. expressed theopinion that the
term “gluten-related disorders” is the umbrella-term to be used for
describing all the conditions related to ingestion of gluten-
containing food [6]. The classiﬁcation covers a wide range of disor-
ders includingallergies (foodallergy, anaphylaxis,wheat-dependent
exercise induced anaphylaxis, baker's asthma, contact dermatitis),
autoimmune diseases (celiac disease, dermatitis herpetiformis,
gluten ataxia) and the diseases that are likely to be immune
* IgE-mediated and non-IgE-mediated















Fig. 2. Classiﬁcation of gluten-related disorders.
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that was held in Munich in 2012, it was noted that besides the IgE-
mediated WA the non-IgE-mediated WA existed as well [6]. This
form of WA may be difﬁcult to distinguish from NCGS [6].
Groups of gluten-related disorders are manifested not only by
disturbances in the gastrointestinal tract, but also by dermatolog-
ical, haematological, endocrinological, rheumatological, gynaeco-
logical, dental and neurological symptoms. After the administration
of a GFD the symptoms disappear. However, when the diet is
abandoned, all the symptoms recur [1].
What is critical for making right diagnostic decisions is to
carefully deﬁne the symptoms and choose such serological tests
and histological imaging of duodenal mucosa that make it possible
to distinguish between different gluten-dependent disorders with
their varying courses, diet protocols, prognoses and complications
[49,50].Conﬂict of interest
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